Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults (Q33487556)

27 July 2017

title

Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults (English)

1 reference

27 July 2017

1 reference

Sydnor TA

1 reference

27 July 2017

Kopp EJ

1 reference

27 July 2017

Anthony KE

1 reference

27 July 2017

LoCoco JM

1 reference

27 July 2017

Kim SS

1 reference

27 July 2017

Fowler CL

1 reference

27 July 2017

publication date

1 April 1998

1 reference

Annals of Allergy, Asthma & Immunology

27 July 2017

published in

1 reference

27 July 2017

1 reference

27 July 2017

1 reference

27 July 2017

page(s)

357-362

1 reference

Acute and chronic sinusitis

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962983-3

7 January 2021

The microbial etiology and antimicrobial therapy of adults with acute community-acquired sinusitis: a fifteen-year experience at the University of Virginia and review of other selected studies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962983-3

7 January 2021

In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962983-3

7 January 2021

Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962983-3

7 January 2021

In vitro susceptibility of penicillin-resistant Streptococcus pneumoniae to levofloxacin, selection of resistant mutants, and time-kill synergy studies of levofloxacin combined with vancomycin, teicoplanin, fusidic acid, and rifampin.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962983-3

7 January 2021

The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962983-3

7 January 2021

Comparative in vitro activity of levofloxacin and ofloxacin against gram-positive bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962983-3

7 January 2021

Levofloxacin in vitro activity against bacteremic isolates of Streptococcus pneumoniae. Franklin County Pneumonia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962983-3

7 January 2021

Susceptibility testing interpretive criteria for levofloxacin when testing respiratory pathogens, Haemophilus influenzae and Moraxella catarrhalis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962983-3

7 January 2021

10.1016/S1081-1206(10)62983-3

Identifiers

DOI

1 reference

27 July 2017

1 reference